CSL Seqirus was one of the drugmakers the federal government listed this week as having its mRNA-related work cut. In an ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

This week, President Donald Trump called Operation Warp Speed, a public-private federal program that helped speed up the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The Trump administration says it is pulling half a billion dollars from U.S. government-funded research projects to create ...

BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the ...

The US Department of Health and Human Services (HHS) has terminated 22 messenger RNA vaccine research projects, totalling ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

TOKYO -- Japanese biotechnology company PrimRNA will launch clinical trials for a treatment using messenger RNA to repair osteoarthritis of the knee, a condition that afflicts many older adults.